PMID- 36823454
OWN - NLM
STAT- MEDLINE
DCOM- 20230508
LR  - 20230512
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 58
IP  - 5
DP  - 2023 May
TI  - Allogeneic stem cell transplantation for patients with acute myeloid leukemia 
      (AML) in second complete remission (CR2) transplanted from unrelated donors with 
      post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia 
      Working Party of the European Society for Blood and Marrow Transplantation.
PG  - 552-557
LID - 10.1038/s41409-023-01940-6 [doi]
AB  - Post-transplant cyclophosphamide (PTCy) is being increasingly used as 
      graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem 
      cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) 
      transplanted in first complete remission (CR1). However, results may differ in 
      patients transplanted in CR2. We retrospectively evaluated transplant outcomes of 
      adult AML patients transplanted between 2010-2019 from 9-10/10 human leukocyte 
      antigen (HLA)-matched unrelated donor (UD) in CR2. In total, 127 patients were 
      included (median age 45.5 years, 54% male). Median follow-up was 19.2 months. 
      Conditioning was myeloablative (MAC) in 50.4% and the graft source was peripheral 
      blood in 93.7% of the transplants. Incidence of acute (a)GVHD II-IV and III-IV 
      was 26.2% and 9.2%. Two-year total and extensive chronic (c)GVHD were 34.3% and 
      13.8 %, respectively. Two-year non-relapse mortality (NRM), relapse incidence 
      (RI), leukemia-free survival (LFS), overall survival (OS), and GVHD-free, 
      relapse-free survival (GRFS) were 17.2%, 21.1%, 61.7, %, 65.2%, and 49.3%, 
      respectively. Time from diagnosis to transplant (>18 months) was a favorable 
      prognostic factor for RI, LFS, OS, and GRFS while favorable risk cytogenetics was 
      a positive prognostic factor for OS. The patient's age was a poor prognostic 
      factor for NRM and cGVHD. Finally, the female-to-male combination and reduced 
      intensity conditioning (RIC) were poor and favorable prognostic factors for 
      cGVHD, respectively. We conclude that PTCy is an effective method for GVHD 
      prophylaxis in AML patients undergoing allo-HCT in CR2 from UD.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Nagler, Arnon
AU  - Nagler A
AUID- ORCID: 0000-0002-0763-1265
AD  - Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. 
      arnon.nagler@sheba.health.gov.il.
FAU - Labopin, Myriam
AU  - Labopin M
AD  - ALWP of the EBMT Paris office, Paris, France.
AD  - Sorbonne University, Department of Haematology, Saint Antoine Hospital, INSERM 
      UMR 938, Paris, France.
FAU - Swoboda, Ryszard
AU  - Swoboda R
AUID- ORCID: 0000-0002-5897-3919
AD  - Department of Bone Marrow Transplantation and Onco-Hematology, Maria 
      Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 
      Gliwice, Poland.
FAU - Kulagin, Alexander
AU  - Kulagin A
AUID- ORCID: 0000-0002-9589-4136
AD  - First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva 
      Memorial Research Institute for Paediatric Oncology, Hematology, and 
      Transplantation, St, Petersburg, Russia.
FAU - Labussiere-Wallet, Helene
AU  - Labussiere-Wallet H
AD  - Centre Hospitalier Lyon Sud, Pavillon Marcel Berard, Service Hematologie, Lyon, 
      France.
FAU - Rovira, Montserrat
AU  - Rovira M
AD  - Hospital Clinic, Department of Hematology, Institute of Hematology and Oncology, 
      Barcelona, Spain.
FAU - Blaise, Didier
AU  - Blaise D
AD  - Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en 
      Cancerologie de Marseille; Institut Paoli Calmettes, Marseille, France.
FAU - Vydra, Jan
AU  - Vydra J
AUID- ORCID: 0000-0002-4274-3895
AD  - Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
FAU - Yakoub-Agha, Ibrahim
AU  - Yakoub-Agha I
AUID- ORCID: 0000-0003-4524-8782
AD  - CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France.
FAU - Choi, Goda
AU  - Choi G
AD  - Deptartment of Hematology; University Medical Center Groningen, University of 
      Groningen, Groningen, The Netherlands.
FAU - Remenyi, Peter
AU  - Remenyi P
AD  - Del-pesti Centrumkorhaz -Orszagos Hematologiai es Infektologiai Intezet; Dept. 
      Haematology and Stem Cell Transplant, Albert, Budapest, Hungary.
FAU - Koc, Yener
AU  - Koc Y
AD  - Medicana International Hospital Istanbul; Bone Marrow Transplant Unit, Istanbul, 
      Turkey.
FAU - Sanz, Jaime
AU  - Sanz J
AUID- ORCID: 0000-0001-6934-4619
AD  - Hospital Universitari i Politecnic La Fe, Valencia, Spain.
FAU - Ciceri, Fabio
AU  - Ciceri F
AUID- ORCID: 0000-0003-0873-0123
AD  - Ospedale San Raffaele s.r.l. Haematology and BMT, Milano, Italy.
FAU - Mohty, Mohamad
AU  - Mohty M
AD  - Sorbonne University, Department of Clinical Hematology and Cellular Therapy, 
      Hospital Saint Antoine, AP-HP, INSERM UMRs 938, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20230223
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Male
MH  - Female
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Unrelated Donors
MH  - Bone Marrow
MH  - Transplantation Conditioning/methods
MH  - Cyclophosphamide/therapeutic use
MH  - *Leukemia, Myeloid, Acute/drug therapy
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Acute Disease
MH  - *Graft vs Host Disease/etiology
MH  - Recurrence
EDAT- 2023/02/25 06:00
MHDA- 2023/05/08 06:41
CRDT- 2023/02/24 00:32
PHST- 2023/01/09 00:00 [received]
PHST- 2023/02/14 00:00 [accepted]
PHST- 2023/02/08 00:00 [revised]
PHST- 2023/05/08 06:41 [medline]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/02/24 00:32 [entrez]
AID - 10.1038/s41409-023-01940-6 [pii]
AID - 10.1038/s41409-023-01940-6 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2023 May;58(5):552-557. doi: 10.1038/s41409-023-01940-6. 
      Epub 2023 Feb 23.